Connect with us

International

FDA issues warning over accidental THC ingestion by children

A number of edible THC products in the US are being mistaken for common foods by children.

Published

on

FDA issues warning over accidental THC ingestion by children
Home » News » International » FDA issues warning over accidental THC ingestion by children

The United States Food and Drug Administration (FDA) has issued a warning that accidental ingestion of THC products by children can lead to serious adverse events.

Some edible THC products in the US are being designed to mimic the image of commonly consumed foods. Using similar brand names, colours and logos on packaging, “copycat” cannabis edibles can easily be mistaken for common foods by children.

With the global cannabis-infused edibles market projected to reach USD$9.03bn (~£7.29bn) by 2026 according to Research and Markets, many brands are selling the likes of THC-infused gummies, drinks and candies.

The FDA has confirmed it received over 100 adverse event reports related to children and adults who consumed edible products containing THC from January 2021 to April, 2022. 

Read more: The problem with “copycat” cannabis edibles

The body has warned consumers that these incidents have caused some to experience adverse events such as hallucinations, increased heart rate and vomiting, with a number requiring medical intervention or hospital admission.

The FDA stated: “Some manufacturers are packaging and labeling edible products containing THC to look like popular brands of commonly consumed foods, such as breakfast cereal, candy, and cookies. These products appeal to children and may be easily mistaken for popular, well-recognised foods.

“The FDA is actively working with federal and state partners to further address the concerns related to these products and monitoring the market for adverse events, product complaints, and other emerging cannabis-derived products of potential concern.”

Read more: Over a third of US THC products too strong for legal sale

A recent study carried out by the NYU School of Global Public Health, and published in Drug and Alcohol Dependence, found that out of the 267 edibles revised in the study, 8 per cent closely resembled 13 different popular snack products, consisting of candies or sweet snacks and one salty snack.

It also found that eight out of 13 packages used the exact brand or product name of popular snack products. Five used names that were similar to popular snack products such as “Stoner Patch Dummies” instead of “Sour Patch Kids”, and seven of the packages used the same cartoon or brand character as the original product.

The study authors warned that this problem should be a major concern for the cannabis industry, and that if these products are not stored properly, children can accidentally ingest them.

The FDA has advised consumers to call emergency services for medical help in the event of an adverse reaction and to ensure products are kept in a safe place out of the reach of children. It has also recommended a local poison centre be called, should a product be ingested by a child.

The FDA stated: “Health care professionals, patients and consumers are encouraged to report complaints and cases of exposure and adverse events to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.”

International

Whitehouse remarks on “wrongful detainment” of Griner for Russian cannabis charges

The basketball star has been sentenced to nine years for allegedly smuggling cannabis medicines into Russia.

Published

on

Whitehouse remarks on “wrongful detainment” of Griner for Russian cannabis charges
Home » News » International » FDA issues warning over accidental THC ingestion by children

American basketball player, Brittney Griner, aged 31, has been sentenced to nine years in prison in Russia after she was caught in possession of cannabis.

As well as a nine-year sentence for possession of vape cartridges containing cannabis, the WNBA star and two-time US Olympic champion has also been ordered to pay a fine of ₽1m (~£13,745).

Some reports have suggested that the development could see the US and Russia negotiating over a prisoner exchange.

Read more: Billy Hood CBD appeal reduces sentence to ten years

President Joe Biden’s office released a statement on the sentencing of what it describes as the “wrongfully detained” Griner, who has been detained since February,

Biden stated: “Today, American citizen Brittney Griner received a prison sentence that is one more reminder of what the world already knew: Russia is wrongfully detaining Brittney. 

“It’s unacceptable, and I call on Russia to release her immediately so she can be with her wife, loved ones, friends, and teammates.

“My administration will continue to work tirelessly and pursue every possible avenue to bring Brittney and Paul Whelan home safely as soon as possible.”

Griner’s agent, Lindsay Kagawa Colas, said the star was being used as a “political pawn”.

In a press briefing by White House press secretary Karine Jean-Pierre and NSC co-ordinator for strategic communications John Kirby, Jean-Pierre stated: “We have repeatedly called for Russia to release her immediately so she can be with her wife, loved ones, friends, and teammates.

“Under President Biden’s direction, the US government continues to work aggressively, pursuing every avenue to bring home Brittney, Paul Whelan, and every American held hostage and wrongfully detained around the world.

“As you all know, we have made a substantial offer to bring her and Paul Whelan home.  We urge Russia to accept that proposal.

“I’m not able to share more publicly at this time, but we are willing to take every step necessary to bring home our people, as we demonstrated with Trevor Reed. And that’s what we’re going to do here. I can assure you this is something the President and our national security team are focused on every single day.”

Griner has 10 days to appeal the verdict.

Continue Reading

International

Flora Growth partners with Colombia’s largest indigenous tribe in joint cannabis venture

“We are honoured to be given the opportunity to work hand-in-hand with the Misak people,” said Luis Merchan, Flora’s Chairman and CEO.

Published

on

Flora Growth Colombia

Flora Growth has entered an agreement with one of Colombia’s main indigenous tribes to process and distribute cannabis products.

Flora Growth has entered into a joint venture agreement with Pharma Indigena Misak Manasr Sas, the largest indigenous tribe in Colombia, on the development of cultivation best practices, manufacturing, export and marketing of cannabis and cannabis-containing products.

Under the agreement, the outdoor cultivator, manufacturer and distributor will provide Manasr regulatory advice, technical and business support related to product development and distribution, promotion of products to be marketed under the Flora brand portfolio, and cannabis derivatives to complete product production.

Additionally, Manasr will work closely with Flora in developing cannabis pharmaceuticals and products and help advance the approvals and authorisations required for exports of cannabis from Colombia.

“We are honoured to be given the opportunity to work hand-in-hand with the Misak people,” said Luis Merchan, Flora’s Chairman and CEO.

“Through this partnership, we will collaborate with the tribe on the processing and distribution of their Colombian-grown cannabis while offering Manasr a powerful platform for product distribution. In return, Flora will be able to leverage the tribe’s unique regulatory positioning to expedite exports and increase global market penetration of Colombian cannabis goods.

“We look forward to a long-standing relationship with such a powerful community partner.”

The initial term of the agreement is three years, however, the intention is to create a “lasting and mutually beneficial relationship for the foreseeable future”, the company said.

This announcement comes two weeks after Flora Growth’s CEO Luis Merchan met with Colombian Senator Gustavo Bolivar, the author of a new bill to legalise recreational cannabis.

Bolivar, the key author of the bill, and Merchan discussed the top tenants of the bill, the bill’s implications for companies such as Flora in Colombia and what legalisation means for the country’s burgeoning domestic and international cannabis markets.

Continue Reading

International

Cresco Pharma to acquire Australia’s Health House for $4.6m

The acquisition will help further Cresco’s presence in Europe and the UK.

Published

on

Cresco Pharma to acquire Australia’s Health House for $4.6m
Home » News » International » FDA issues warning over accidental THC ingestion by children

Cresco Pharma is to acquire 100 per cent of Health House International (HHI) under a non-binding term sheet agreement.

Switzerland-based Medical cannabis product developer, Cresco Pharma, has said that the $4.6m (~£3.76m) acquisition of international medical cannabis distributor, Health House, will unlock a number of new markets for the company across the UK, Europe and Australia. 

The acquisition is subject to Creso completing satisfactory due diligence on Health House’s businesses.

Read more: Agreement reached for landmark Columbia Care deal

Group CEO and managing director of Cresco Pharma, William Lay, said: “The proposed acquisition of Health House has a number of potential benefits for Creso Pharma. 

“Subject to a formal Scheme  Implementation Deed being executed, implementation of the scheme would result in Creso Pharma significantly strengthening its global distribution capabilities and unlocking a number of new markets across the  UK, Europe and Australia. 

“The company intends to undertake due diligence on Health House’s operations immediately and explore the potential to leverage the group’s existing relationships for Creso Pharma’s own product ranges.

“Further, the company will investigate other potential opportunities including HHI’s existing EU-GMP product manufacturing capabilities and how these can further benefit Mernova, SSH and  Creso Switzerland as we push to establish a presence in Europe and the UK.

“We look forward to progressing work towards implementation of the Scheme and will provide ongoing updates as due diligence requirements are met and additional opportunities materialise.”  

The news follows the failed merger between Health House and Zelira Therapeutics Limited. The proposed acquisition was terminated due to a “substantial change in market conditions since the scheme was originally announced”. 

Health House currently has supply agreements in place with several pharmaceutical grade GMP-certified manufacturers and producers of medicinal cannabis products, and also owns a medicinal cannabis consultancy in the EU.

The company is currently supporting a non-interventional study in Germany, launched by another Health House group company, that considers the effect on quality of life of patients and the safety and tolerability of cannabis medication.

Recently, Health House announced that its wholly-owned subsidiary CanPharma GmbH has continued its strategy to enter into preferred supplier agreements with German statutory health insurance (SHI) funds, securing agreements with five funds to date. 

CanPharma’s latest agreement with Techniker Krankenkasse, the largest German statutory health insurance fund represents more than 10 million insured individuals, bringing the total number of patients that SHI funds cover, with preferred supplier agreements with CanPharma, to over 35 million, representing almost 50 per cent of the total number of insured Germans. 

Creso Pharma has stated that the proposed acquisition of Health House would create a global organisation with strong medicinal cannabis production and distribution capabilities, as well as a growing revenue profile. However, it emphasises that, until due diligence is completed and a binding Scheme Implementation Deed is executed by the parties, there is no certainty that the acquisition of Health House will proceed.

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts

[class^="wpforms-"]
[class^="wpforms-"]